Key Takeaways
- • Aidoc raised $150 million in Series E funding led by Goldman Sachs Alternatives Growth Equity, with participation from General Catalyst, SoftBank Investment Advisors, and NVIDIA Ventures (NVentures).
- • The round brings Aidoc's total funding to over $500 million in less than one year following a prior growth round, signaling accelerating investor confidence in enterprise-scale clinical AI.
- • The funding round demonstrates sustained institutional appetite for clinical artificial intelligence solutions across multiple tier-one investors spanning growth equity, venture capital, and strategic corporate investors.
Summary
Aidoc, a clinical AI platform, has completed a $150 million Series E funding round led by Goldman Sachs Alternatives' Growth Equity division. The round attracted participation from three additional institutional investors: General Catalyst, SoftBank Investment Advisors, and NVentures, NVIDIA's corporate venture capital arm. This capital raise represents a significant validation of Aidoc's market position and technology.
The funding round is particularly notable given the velocity of Aidoc's capital raises. The company exceeded $500 million in total funding in less than a year, following a prior growth round led by General Catalyst and Square Peg Capital. This rapid deployment of capital underscores both the competitive intensity among growth equity investors to secure allocation in clinical AI and the demonstrated traction Aidoc has achieved in enterprise healthcare deployments.
The composition of investors participating in this round reflects the breadth of institutional interest in clinical AI infrastructure. Goldman Sachs' direct leadership of the round signals conviction from a major financial services firm with significant alternative asset management capabilities. The inclusion of SoftBank Investment Advisors and NVIDIA Ventures indicates that both multi-stage technology investors and strategic semiconductor players view clinical AI as a priority sector. General Catalyst's continued participation suggests validation of earlier investment theses.
For institutional investors evaluating exposure to clinical AI, this round demonstrates that the market has moved beyond early-stage venture funding into sustained growth equity territory, with larger check sizes and more established institutional capital sources committing to category leaders. The pace of fundraising suggests Aidoc is positioned as a tier-one player in the competitive clinical AI market.
The funding round is particularly notable given the velocity of Aidoc's capital raises. The company exceeded $500 million in total funding in less than a year, following a prior growth round led by General Catalyst and Square Peg Capital. This rapid deployment of capital underscores both the competitive intensity among growth equity investors to secure allocation in clinical AI and the demonstrated traction Aidoc has achieved in enterprise healthcare deployments.
The composition of investors participating in this round reflects the breadth of institutional interest in clinical AI infrastructure. Goldman Sachs' direct leadership of the round signals conviction from a major financial services firm with significant alternative asset management capabilities. The inclusion of SoftBank Investment Advisors and NVIDIA Ventures indicates that both multi-stage technology investors and strategic semiconductor players view clinical AI as a priority sector. General Catalyst's continued participation suggests validation of earlier investment theses.
For institutional investors evaluating exposure to clinical AI, this round demonstrates that the market has moved beyond early-stage venture funding into sustained growth equity territory, with larger check sizes and more established institutional capital sources committing to category leaders. The pace of fundraising suggests Aidoc is positioned as a tier-one player in the competitive clinical AI market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.